A DNA dendrimer immunoassay reagent and method
By designing specific DNA probes and additives, using the combination of fluorescence and quenching groups, the detection efficiency and sensitivity of BHCR reaction reagents are improved, the problem of low detection efficiency in the prior art is solved, and faster and more accurate test results.
Patent Information
- Application Number
- CN202111308240.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-11-05
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-11-05
AI Technical Summary
The detection efficiency and time of BHCR reaction reagents in existing instant inspection techniques need to be improved, which affects the accuracy and sensitivity of the detection results.
Using specific DNA probe sequences and additive designs, including trigger probes, FA probes, QA probes, FB probes, QB probes, and assist A and B, the combination of fluorescence and quenching groups can be achieved. Secondary or exponential amplification to improve the strength and stability of the detection signal.
It significantly improves detection efficiency and sensitivity, shortens detection time, and improves the stability and accuracy of the reagents, making it suitable for clinical immediate testing applications.
Smart Images

Figure BDA0003340908060000101 
Figure BDA0003340908060000111 
Figure BDA0003340908060000112
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a DNA dendrimer immune detection reagent and method. Background Art
[0002] Point-of-care testing (POCT) is a test performed at the patient's bedside, mainly used in physical examination centers, emergency departments, intensive care units, outpatient departments and other departments. The main examination items include: tumor marker detection, cardiac marker detection, inflammatory marker detection, kidney marker detection or blood glucose marker detection. Its detection methods mainly include isotope radioimmunoassay (RIA), colloidal gold, enzyme-linked immunosorbent assay (ELISA), time-resolved fluorescence (TRFIA) and chemiluminescence (CLIA). The core steps of these detection methods mainly include two parts, one is to achieve recognition of the analyte through immune reaction, and the other is to make the immune reaction product generate a signal and identify and report it. It can be seen that the detection and reporting of the signal generated by the immune reaction will have a crucial impact on the accuracy and sensitivity of the test results.
[0003] Nonlinear hybridization chain reaction (BHCR) can easily achieve quadratic or exponential amplification. Nonlinear hybridization chain reaction is a hairpin-free nonlinear HCR system. The system mainly includes double-stranded substrate-A, substrate-B and corresponding auxiliary agents A and auxiliary agents B labeled with fluorophores and quenchers. The growth of chain branches is controlled by quenched substrate kinetics to produce fluorescent DNA dendrimers, achieving quadratic or exponential amplification. Its conditions are mild, no enzymes are required, the scheme is simple, and the amplification efficiency is excellent. Therefore, BHCR can be combined with a variety of detection methods to establish biosensors for ultrasensitive detection of various low-content analytes. However, the nonlinear hybridization chain reaction time and detection efficiency of BHCR reaction reagents in the prior art need to be improved. Summary of the invention
[0004] In view of this, the technical problem to be solved by the present invention is to provide a real-time testing reagent and method for improving the detection efficiency.
[0005] The BHCR reaction reagent provided by the present invention,
[0006] Including: trigger probe, FA probe, QA probe, auxiliary A, FB probe, QB probe and auxiliary B;
[0007] The sequence of the trigger probe consists of an isolation region and a trigger recognition region; the trigger recognition region consists of sequentially connected fragments a, b, and c.
[0008] The sequence of the FA probe consists of 2 repeating units and a reverse complementary sequence of the trigger recognition region; each of the repeating units consists of sequentially connected fragments x, y and z;
[0009] The sequence of the auxiliary A is composed of the reverse complementary sequence of 2 fragments y and 1 fragment c;
[0010] The sequence of the QA probe consists of reverse complementary sequences of fragment b, fragment c and two fragments y;
[0011] The sequence of the FB probe consists of a reverse complementary sequence of one repeating unit and the trigger recognition region sequence;
[0012] The sequence of the auxiliary B is the reverse complementary sequence of 18 bp at the 5' end of the QB probe;
[0013] The sequence of the QB probe consists of a reverse complementary sequence of the trigger recognition region lacking 7 bp at the 5' end, and a repeating unit sequence lacking 5 bp at the 3' end.
[0014] In the present invention, the isolation region sequence of the trigger probe is ployA; the nucleic acid sequence of the trigger recognition region is TGACGAACTAGTTGATGAAGCTG, wherein the fragment a is TGACG, the fragment b is AACTAGTTGATG, and the fragment c is AAGCTG. In some embodiments, the isolation region is AAAAA.
[0015] In the present invention, the sequence of the repeating unit is GTGTGCCTATTATGTCTCCTCCT, wherein the fragment x is GT, the fragment y is GTGCCTATTATGTC, and the fragment z is TCCTCCT.
[0016] In some embodiments, the 5' end of the trigger probe is labeled with biotin, the 5' ends of FA and QB are labeled with a fluorescent group, and the 3' ends of FB and QA are labeled with a quencher group. In some embodiments, the fluorescent group is 6-FAM, and the quencher group is BHQ1.
[0017] In the present invention, the BHCR reaction reagent is used in the preparation of instant test reagents.
[0018] The present invention also provides a reagent for instant testing, which includes a trigger probe, a reagent A, a reagent B, a reagent C and a reagent D;
[0019] The reagent A includes a FA probe, a QA probe and an auxiliary A;
[0020] The reagent B includes FB probe, QB probe and auxiliary B;
[0021] The reagent C comprises magnetic beads coated with capture antibodies;
[0022] The trigger probe and the detection antibody labeled with avidin form a complex, which is recorded as reagent D;
[0023] Alternatively, the detection antibody labeled with avidin is recorded as reagent D, and the trigger probe existing independently is recorded as reagent E.
[0024] In the present invention, the preparation of the reagent A comprises: cooling the FA probe and the QA probe from 90-95°C to 55°C at a rate of 1 min / °C, then cooling them naturally to room temperature, and then adding auxiliary A to obtain the reagent A.
[0025] In the present invention, the preparation of the reagent B comprises: cooling the FB probe and the QB probe from 90-95°C to 55°C at a rate of 1 min / °C, then cooling them naturally to room temperature, and then adding auxiliary B to obtain reagent B.
[0026] In the present invention, the preparation of the complex formed by the trigger probe and the detection antibody labeled with avidin includes: after labeling the detection antibody with avidin, mixing it with the trigger probe in PBS containing 0.5% BSA, and incubating to obtain the complex.
[0027] In some embodiments, the capture antibody is selected from a tumor marker antibody, a cardiac marker antibody, an inflammatory marker antibody, a kidney marker antibody or a blood glucose marker antibody.
[0028] The detection antibody is an anti-antibody. In a specific embodiment, the detection antibody is an anti-human antibody. For example, rabbit anti-human antibody, mouse anti-human antibody or goat anti-human antibody.
[0029] In some specific embodiments, the tumor marker antibodies include AFP, PSA, carcinoembryonic antigen (CEA), cancer antigen 242 (CA242), neuronal isoenolase NSE, serum ferritin (SF), progastrin releasing peptide (PROGRP) or squamous cell carcinoma antigen (SCC).
[0030] The present invention also provides an instant detection method, which uses the reagent provided by the present invention to detect the object to be detected.
[0031] In some embodiments, the detection method includes:
[0032] The carrier of the capture antibody is incubated with the analyte, and then reacted with the detection antibody labeled with avidin to obtain product I; the trigger probe, reagent A and reagent B are incubated together to obtain product II; after incubating product I and product II together, the signal is detected.
[0033] In other embodiments, the detection method includes:
[0034] The trigger probe is reacted with avidin and detection antibody to obtain product i; the carrier of the capture antibody is incubated with the test object and then reacted with product i to obtain product ii; reagent A and reagent B are incubated together to obtain product iii; product ii is reacted with product iii to detect the signal.
[0035] In some embodiments, the analyte is a sample from blood, tissue, excrement or secretion. In an embodiment of the present invention, the sample is a blood sample.
[0036] In the detection reagent provided by the present invention, the design of the auxiliary B can reduce the speed of molecular chain decomposition, thereby improving stability, and is more suitable for clinical instant detection of biomarkers, with lower background signals, thereby making the detection more sensitive and accurate. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The reaction principle of the reagent of the present invention is shown. DETAILED DESCRIPTION
[0038] The present invention provides instant test reagents and methods, and those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The methods and applications of the present invention have been described through preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the methods and applications of this article without departing from the content, spirit and scope of the present invention to implement and apply the technology of the present invention.
[0039] The BHCR reaction reagent provided by the present invention comprises: a trigger probe, a FA probe, a QA probe, an auxiliary A, a FB probe, a QB probe and an auxiliary B.
[0040] The various probes in the reaction reagents of the present invention are all DNA, more preferably single-stranded DNA. The sequence thereof is not strictly limited, and the detection effect can be achieved as long as the conditions described in the present invention are met.
[0041] The BHCR reaction reagent provided by the present invention is used to detect the product after the antigen-antibody reaction to achieve amplification of the detection signal. In the antigen-antibody reaction, the capture antibody coated on the matrix can capture the antigen in the test object, and the detection antibody with the biomarker recognizes the antigen, thereby connecting the biomarker to the antigen through the detection antibody.
[0042] In the present invention, the sequence of the trigger probe consists of an isolation region and a trigger recognition region, which is also modified with biotin or avidin. When the detection antibody is labeled with biotin, the trigger probe is labeled with avidin. When the detection antibody is labeled with avidin, the trigger probe is labeled with biotin. In the present invention, the marker of the trigger probe is located at its 5' end. In some embodiments, the structure of the trigger probe is biotin-isolation region-trigger recognition region. In some specific embodiments, the sequence of the isolation region is polyA, and the sequence of the trigger recognition region is not limited, and it can be reverse complementary to a part of FA. The length of the trigger recognition region is 25 to 30, and in the present invention, its length is 28bp. In some specific embodiments, the structure of the trigger probe is: biotin-AAAAATGACGAACTAGTTGATGAAGCTG. Among them, in order to facilitate the description of the relationship between the structure of other probes in the reagent and the trigger probe, the trigger recognition region is divided into three fragments. Therefore, the trigger recognition region is composed of sequentially connected fragments a, b, and c, wherein fragment a is TGACG, fragment b is AACTAGTTGATG, and fragment c is AAGCTG.
[0043] In the present invention, the sequence of the FA probe is composed of n repeating units and a reverse complementary sequence of the trigger recognition region; in order to conveniently describe the relationship between the structure of other probes in the reagent and the FA probe, each of the repeating units is divided into 3 fragments, and each of the repeating units is composed of sequentially connected fragments x, fragment y and fragment z. The structure of the FA probe of the present invention can be expressed as: (fragment x-fragment y-fragment z)n-reverse complementary fragment of the trigger recognition region.
[0044] In the detection process of the reaction reagent provided by the present invention, each repeating unit in the FA probe can be combined with an FB probe. Since each FA includes more than 3 repeating units, each FA in the reaction reagent provided by the present invention can be combined with at least 3 FBs. Thereby improving the efficiency and sensitivity of the detection. The present invention designs FA to be combined with 2 FBs, FA to be combined with 3 FBs, and FA to be combined with 4 FBs, and reacts for 5 minutes respectively. The results show that as the number of repeating units increases, the fluorescence intensity obtained in the same time increases. Although in theory the fluorescence intensity will continue to increase with the increase in the number of repeating units, in order to improve the stability of the reaction, the length of FA is not more than 300bp.
[0045] In some embodiments of the present invention, the sequence of the repeating unit is GTGTGCCTATTATGTCTCCTCCT, wherein the fragment x is GT, the fragment y is GTGCCTATTATGTC, and the fragment z is TCCTCCT. In some embodiments, the number of the repeating units is 3 or 4. Compared with the FA probe with two repeating units, the probe with more than 3 repeating units in the present invention has a higher sensitivity and a shorter detection cycle.
[0046] In the present invention, the 5' end of the FA probe is modified with a fluorescent group. The fluorescent group is selected from Alexa350, Alexa488, Alexa 532, Alexa 549, Alexa 647, Alexa 680, CF350, CF488, CF532, CF594, CF647, CF680, 6-FAM, FITC, TRITC, 6-TET HEX, VIC, ROX, Cal610, Texas Red, CY5, Quasar670 or Quasar705;
[0047] In some specific embodiments, n=3, and the structure of the FA probe is:
[0048] 6-FAM-GTGTGCCTATTATGTCTCCTCCTGTGTGCCTATTATGTCTCCTCCTGTGTGCCTATTATGTCTCCTCCTCAGCTTCATCAACTAGTTCGTCA;
[0049] In some other specific embodiments, n=4, and the structure of the FA probe is:
[0050] 6-FAM-GTGTGCCTATTATGTCTCCTCCTGTGTGCCTATTATGTCTCCTCCTGTGTGCCTATTATGTCTCCTCCTGTGTGCCTATTATGTCTCCTCCTCAGCTTCA TCAACTAGTTCGTCA.
[0051] In the present invention, the sequence of the QA probe is composed of fragment b, fragment c, and n reverse complementary sequences of fragment y in the trigger probe. Its structure can be expressed as: fragment b-fragment c-(reverse complementary fragment of fragment y) n. In QA, the value of n is equal to the value of n in FA. Wherein, the sequence of the reverse complementary fragment of fragment y is GACATAATAGGCAC AC.
[0052] The 3' end of the QA is modified with a quenching group. The quenching group on the QA probe can quench the fluorescent group on the FA probe. The quenching group is selected from BHQ-0, BHQ-1, BHQ-2, BHQ-3, MGB, DabCyl or Eclip seλ.
[0053] In some embodiments, n=3, and the structure of QA is:
[0054] AACTAGTTGATGAAGCTGGACATAATAGGCACACGACATAATAGGCACAC / GACATAATAGGCACAC-BHQ1
[0055] In some other embodiments, n=4, and the structure of QA is:
[0056] AACTAGTTGATGAAGCTGGACATAATAGGCACACGACATAATAGGCACAC / GACATAATAGGCACACGACATAATAGGCACAC-BHQ1
[0057] The sequence of the auxiliary A of the present invention is composed of the reverse complementary sequence of n fragments y and 1 fragment c; its structure can be expressed as (fragment y)n-reverse complementary sequence of fragment c. The value of n is equal to the value of n in FA. The reverse complementary sequence of fragment c is CAGCTT. No fluorescent group or quenching group is modified on the auxiliary A.
[0058] In some embodiments, n=3, the structure of the auxiliary A is:
[0059] GTGCCTATTATGTCGTGCCTATTATGTCGTGTGCCTATTATGTCCAGCTT
[0060] In some other embodiments, n=4, the structure of the auxiliary A is:
[0061] GTGCCTATTATGTCGTGCCTATTATGTCGTGCCTATTATGTCGTGTGCCTATTATGTCCAGCTT
[0062] The preparation of the reagent A of the present invention comprises: cooling the FA probe and the QA probe from 90-95°C to 55°C at a rate of 1 min / °C, and then cooling them naturally to room temperature, and then adding auxiliary A to obtain the reagent A.
[0063] In the preparation process of the reagent A described in the present invention, the FA and QA are denatured at 95°C for 5 minutes, and then slowly cooled to room temperature within 30 minutes. According to the principle of base complementary pairing, the FA chain and the QA chain form a complementary double chain. However, the fragment z is not complementary to the fragment on QA, forming a stem-loop structure. In the double chain formed by FA and QA, the distance between the fluorescent group and the quenching group is very close, resulting in the fluorescence on the FA probe being in a "quenched" state.
[0064] The sequence of the FB probe of the present invention consists of a reverse complementary sequence of one repeating unit and a trigger recognition region sequence identical to the trigger probe. That is, the structure of the FB probe can be expressed as: reverse complementary sequence of the repeating unit-trigger recognition region sequence. The number of reverse complementary sequences of the repeating units on the FB probe is only one, and does not change due to changes in the number of repeating units in FA. Among them, the reverse complementary sequence of the repeating unit is AGGAGGAGACATAATAGGCACAC.
[0065] The 3' end of the FB probe is modified with a quenching group, and the quenching group is selected from BHQ-0, BHQ-1, BHQ-2, BHQ-3, MGB, DabCyl or Eclip seλ.
[0066] In some specific embodiments, the structure of the FB probe is:
[0067] AGGAGGAGACATAATAGGCACACTGACGAACTAGTTGATGAAGCTG-FAM.
[0068] The QB probe sequence of the present invention is composed of a reverse complementary sequence of a trigger recognition region with 7 bp missing from the 5' end, and a repeating unit sequence with 5 bp missing from the 3' end. That is, the structure of the QB probe can be expressed as: reverse complementary (trigger recognition region 5' end -7bp)-(repeat unit 3' end -5bp). Among them, the 5' end -7bp of the trigger recognition region is CTAGTTGATGAAGCTG, and its reverse complementary sequence is CAGCTTCATCAACTAG. The 3' end -5bp of the repeating unit is GTGTGCCTATTATGTCTC. In the present invention, the 5' end of the QB probe is modified with a fluorescent group. The quenching group modified on the FB probe can quench the fluorescent group on the QB probe. The quenching group modified on the QB probe is Alexa350, Alexa488, Alexa 532, Alexa549, Alexa 647, Alexa 680, CF350, CF488, CF532, CF594, CF647, CF680, 6-FAM, FITC, TRITC, 6-TET HEX, VIC, ROX, Cal610, Texas Red, CY5, Quasar670 or Quasar705.
[0069] The sequences of the auxiliary B described in the present invention are reverse complementary to those of the QB probe. Specifically, the auxiliary B is reverse complementary to the sequence of 18 to 20 bp at the 5' end of the QB probe. Among them, the 20 bp sequence at the 5' end of the QB probe is: CAGCTTCATCAACTAGGTGTGC, the sequence of the auxiliary B is GCACACCTAGTTGATGAAGC, or the sequence of the auxiliary B is CACACCTAGTTGATG AAGC, or the sequence of the auxiliary B is ACACCTAGTTGATG AAGC. The present invention attempts the length of the auxiliary B, and the results show that an auxiliary B length of 18 bp is more conducive to reducing the decomposition rate, thereby improving the stability of the reaction. Therefore, when the length of the auxiliary B is 18 bp, its effect is better than the detection effect of a length of 19 bp or 20 bp, and the fluorescence signal obtained by detecting with an 18 bp auxiliary B within 35 minutes is more significant.
[0070] The preparation of the reagent B of the present invention comprises: cooling the FB probe and the QB probe from 90-95°C to 55°C at a rate of 1 min / °C, then cooling them naturally to room temperature, and adding auxiliary B to obtain the reagent B.
[0071] In the preparation process of the reagent B described in the present invention, the FB and QB are denatured at 95°C for 5 minutes, and then slowly cooled to room temperature within 30 minutes. According to the principle of base complementary pairing, the FB chain and the QB chain form a complementary double chain. In the double chain formed by FB and QB, the distance between the fluorescent group and the quenching group is very close, resulting in the fluorescence on the FB probe being in a "quenched" state.
[0072] The biotin label on the trigger probe contained in the reaction reagent of the present invention can identify the product with streptavidin label after the antigen-antibody reaction. In addition, when reagent A and reagent B are added to the system, the trigger hybridizes and docks with the exposed foothold on the FA probe, resulting in a branch migration reaction, displacing part of the Q chain from the F chain and opening the first loop, and then auxiliary A displaces the Q chain by docking to the newly exposed foothold, and produces a byproduct. By dissociating the Q chain with the quenching group from the F chain, the fluorescence in the F chain is restored. The F chain in the substrate chain A exposes two identical sequences connected in series, which can be hybridized with the footholds of the two substrate chains B at the same time. With the help of the auxiliary chain Ass B or Ass B-2nt, the Q chain is displaced and the byproduct B is produced, and more fluorescent reporter groups are released; and two single-stranded regions composed of the same sequence as the trigger chain DNA are exposed to enter a new round of reaction. Through the cyclic reaction, a dendritic nanocomplex is finally formed, and more byproducts A and byproducts B are produced ( Figure 1 ).
[0073] The invention discloses an application of a BHCR reaction reagent in preparing a point-of-care test reagent.
[0074] The present invention also provides a reagent for instant testing, which includes the BHCR reaction reagent of the present invention, magnetic beads coated with capture antibodies, and detection antibodies labeled with avidin. In the prior art, it is generally believed that probes or enzymes cannot be mixed and stored, which will lead to a decrease in detection effect. However, the present invention has found through experiments that mixing some reagents or forming a complex for storage can not only shorten the time of clinical testing, but also obtain good detection stability.
[0075] For example: The instant detection reagents provided by the present invention include:
[0076] Reagent A: FA probe + QA probe + Auxiliary A. Auxiliary A was added after FA and QA formed a double strand, and reagent A was stored at 4°C.
[0077] Reagent B: FB probe + QB probe + auxiliary B. After FB and QB form a double strand, auxiliary B is added and reagent B is stored at 4°C.
[0078] Reagent C: magnetic beads + antibodies. It is prepared by coating magnetic beads with antibodies. The connection between the magnetic beads and the antibodies is covalent coupling. The magnetic beads are surface-modified with carboxyl, amino or thiol groups. The particle size is 100nm to 5μm. The preferred particle size is 1μm to 3μm. Store at 4°C.
[0079] Reagent D: detection antibody, streptavidin; wherein, the detection antibody labeled with streptavidin plays a connecting role, and the detection antibody can be a monoclonal antibody or a polyclonal antibody, which is connected to streptavidin.
[0080] Reagent E: trigger probe.
[0081] Among the reagents, it has been experimentally verified that reagents A, B and D can remain stable within 3 months, and can still obtain good detection results after being placed at 4°C for 3 months. Reagent C can be stored at 4°C for 2 years, and reagent E can be stored at 4°C for 12 months without affecting the test results.
[0082] Alternatively, the instant detection reagent provided by the present invention includes:
[0083] Reagent A: FA probe + QA probe + Auxiliary A. Auxiliary A was added after FA and QA formed a double strand, and reagent A was stored at 4°C.
[0084] Reagent B: FB probe + QB probe + auxiliary B. After FB and QB form a double strand, auxiliary B is added and reagent B is stored at 4°C.
[0085] Reagent C: magnetic beads + antibodies. It is prepared by coating magnetic beads with antibodies. The connection between the magnetic beads and the antibodies is covalent coupling. The magnetic beads are surface-modified with carboxyl, amino or thiol groups. The particle size is 100nm to 5μm. The preferred particle size is 1μm to 3μm. Store at 4°C.
[0086] Reagent D: detection antibody, streptavidin, trigger probe; among them, the detection antibody labeled with streptavidin plays a connecting role. The detection antibody can be a monoclonal antibody or a polyclonal antibody, and the label is mainly connected with streptavidin. Incubate the detection antibody modified with streptavidin with the trigger probe at 30-37℃ for 0-0.1h to form complex A. Based on the structural characteristics of streptavidin and trigger probe, streptavidin can be connected with 4 trigger DNAs. Store at 4℃.
[0087] Among the reagents, it has been experimentally verified that reagents A, B and D can remain stable within 3 months, and can still obtain good detection results after being placed at 4°C for 3 months. Reagent C can be stored at 4°C for 2 years without affecting the test results.
[0088] The capture antibody in the detection reagent of the present invention can be a polyclonal antibody or a monoclonal antibody. Preferably, it is a monoclonal antibody. If the antibody contains other amino or thiol impurity molecules, the impurity molecules need to be removed by dialysis, G-25, etc. to avoid competitive reaction to the antibody (such as Tris, glycine, BSA, etc.). The preparation method of the magnetic beads coated with antibodies mainly includes: placing the magnetic beads in a coupling reaction bottle, adding buffer, and then adding antibodies (magnetic beads mg: antibody mg = 20:1), tightening the coupling reaction bottle and placing it in a constant temperature shaker, shaking at a constant temperature of 25°C for 1-6 hours, ensuring that the shaking is mixed, adding buffer to the coupling reaction bottle for washing (magnetic separation method, removing the supernatant), blocking the unreacted active groups (3%-5% BSA), and storing in a refrigerator at 4°C.
[0089] The present invention also provides a method for instant detection, which comprises: incubating a carrier of a capture antibody with a test object, and then reacting with a detection antibody labeled with avidin to obtain a product I; incubating a trigger probe, a reagent A and a reagent B together to obtain a product II; and after incubating the product I and the product II together, detecting a signal.
[0090] Alternatively, the instant detection method includes: reacting the trigger probe with avidin and a detection antibody to obtain product i; incubating a carrier of the capture antibody with the object to be detected and reacting with product i to obtain product ii; incubating reagent A and reagent B together to obtain product iii; reacting product ii with product iii to detect the signal.
[0091] In the method of the present invention, since part of the detection reagent has already reacted to form a complex before clinical detection, it does not need to be prepared immediately when used clinically, thereby greatly shortening the detection time without affecting the accuracy of the detection.
[0092] In the present invention, the object to be detected is a sample from blood, tissue, excrement or secretion. In an embodiment of the present invention, the sample is a blood sample. Specifically, the blood sample is serum or plasma.
[0093] The test materials used in the present invention are all common commercial products and can be purchased on the market. The present invention is further described below in conjunction with the embodiments:
[0094] Example 1
[0095] The effects of different probes were verified by testing the PSA standard with a specific concentration. The experiment was divided into the following groups:
[0096] The probe sequences in the reagents of group 1 are:
[0097]
[0098] The probe sequences in Group 2 reagents are:
[0099]
[0100] The probe sequences in Group 3 reagents are:
[0101]
[0102] As mentioned above, the BHCR reaction solution includes reagent A, reagent B and buffer.
[0103] 1.1. Reagent A is prepared by the following method: put F-strand of substrate-A (FA) and Q-strand of substrate-A (QA) into a PCR instrument at 90-95 degrees, cool to 55 degrees at 1min / ℃, then take out and cool to room temperature and add auxiliary A to obtain reagent A. FA and QA first become double strands, taking the probe design of group 1 as an example, double strands are formed. Store at 4℃ and it can be stored for 3 months.
[0104] 1.2. Reagent B is prepared by the following method: put F-strand of substrate-B (FB) and Q-strand of substrate-B (QB) into a PCR instrument at 90-95°C, cool to 55°C at 1min / °C, then take out and cool to room temperature and add auxiliary B to obtain reagent B. FB and QB become double strands. Taking the probe design of group 1 as an example, double strands are formed. Store at 4°C and it can be stored for 3 months.
[0105] 1.3. Reagent C is made of magnetic beads + PSA antibody
[0106] After the surface of superparamagnetic carboxyl magnetic beads is activated, they are coupled with PSA antibodies and blocked to obtain reagent C. The buffer of reagent C is PBS, pH 7.4, with 0.09% sodium azide and 0.01% Tween 20. The density of the magnetic beads is 50 mg / ml. It can be stored at 4°C for 2 years.
[0107] 1.4: Reagent D is made from detection antibody + streptavidin + trigger DNA:
[0108] First, prepare the detection antibody labeled with streptavidin, then add the trigger probe, react at 30-37°C for 1 hour, and prepare reagent D. The buffer of reagent D is 0.5% PBS. Store at 4°C and it can be stored for 12 months.
[0109] 2. Use the above reagents to test the PSA standard (concentration 4 ng / ml), the steps include:
[0110] 2.1. Mix reagent C and standard sample at 25℃, incubate for 30 minutes, and collect magnetic beads;
[0111] 2.2. The magnetic beads collected in step 2.1 were mixed with reagent D and reacted at 25°C for 40 minutes;
[0112] 2.3. Mix reagent A and reagent B and react at 37°C for 20 minutes;
[0113] 2.4. Place the solution in step 2.3 in step 2.2 and react at 37°C for 15-30 minutes;
[0114] 2.5. Remove the supernatant in step 2.4 by magnetic separation, wash the magnetic beads with PBST or PBS solution, and Ultra-high sensitivity multicolor flow cytometer to detect fluorescence intensity
[0115] The results showed that the average fluorescence values obtained by groups 1 to 3 were repeated 5 times: group 1: 11000, group 2: 12000, group 3: 13800. It can be seen that as the number of repeating units increases, the fluorescence intensity detected within a certain reaction time increases, and the fluorescence intensity of groups 2 and 3 is significantly stronger than that of group 1. However, further increasing the number of repeating units will lead to unstable reactions, so the preferred number of repeating units is 3 to 4.
[0116] Example 2
[0117] 1. Design the following sets of primers: Trigger, FA, QA, FB, QB in each set remain unchanged, and their sequences are as follows:
[0118]
[0119]
[0120] 2. The preparation method of reagents A to D is the same as that of Example 1. The PSA standard (concentration 4 ng / ml) is tested with each group of reagents. The steps include:
[0121] 2.1. Mix reagent C and standard sample at 25℃, incubate for 30 minutes, and collect magnetic beads;
[0122] 2.2. The magnetic beads collected in step 2.1 were mixed with reagent D and reacted at 25°C for 40 minutes;
[0123] 2.3. Mix reagent A and reagent B and react at 37°C for 20 minutes;
[0124] 2.4. Place the solution in step 2.3 in step 2.2 and react at 37°C for 15-30 minutes;
[0125] 2.5. Remove the supernatant in step 2.4 by magnetic separation, wash the magnetic beads with PBST or PBS solution, and Ultra-high sensitivity multicolor flow cytometer to detect fluorescence intensity
[0126] The results showed that the average fluorescence values of groups 1 to 3 were repeated 5 times, and the average fluorescence values were: group 1: 11000, group 2: 11600, group 3: 12800. It can be seen that by reducing the length of auxiliary B, the structure is not easy to open spontaneously, thereby achieving the purpose of reducing the background. Among them, when the length of auxiliary B is 18bp, the fluorescence value is higher, the linearity of the fluorescence growth curve over time is better, and the background is lower.
[0127] Example 3
[0128] In order to shorten the clinical testing time, attempts are made to react the reagents to form complexes before testing to avoid “preparation on demand” in clinical testing.
[0129] The experiment includes the following contents: each component is stored separately, prepared before detection, and tested within 12 hours with PSA standard (concentration of 4ng / mL) as the test object, and the fluorescence intensity is recorded. Then, each reagent is stored for a period of time (1 month, 2 months, 3 months, 6 months, 12 months, 18 months, 24 months) after preparation, and then tested again to analyze the difference in detection effect with the reagent that has not been stored. If the difference is within 3%, it is considered that there is no effect on the reaction effect.
[0130] 1. Cool the FA probe and QA probe from 90-95°C to 55°C at a rate of 1 min / °C, and then cool naturally to room temperature, then add reagent A to obtain reagent A. The reagent does not affect the detection effect after being stored at 4°C for 3 months, but the detection effect decreases thereafter.
[0131] 2. The FB probe and QB probe were cooled from 90-95°C at a rate of 1 min / °C to 55°C, and then naturally cooled to room temperature, and then reagent B was added to obtain reagent B. The reagent was stored at 4°C for 3 months without affecting the detection effect, but the detection effect was reduced thereafter.
[0132] 3. The preparation method of antibody-modified magnetic beads includes placing the magnetic beads in a coupling reaction bottle, adding a buffer solution, and then adding the antibody (magnetic bead amount mg: antibody amount mg = 20:1), tightening the coupling reaction bottle and placing it in a constant temperature shaker, shaking at a constant temperature of 25°C for 1-6 hours to ensure that the shaking is mixed, adding a buffer solution to the coupling reaction bottle for washing (magnetic separation method, removing the supernatant), blocking the unreacted active groups (3%-5% BSA), and storing it in a refrigerator at 4°C. It remains stable for 2 years.
[0133] 4. The detection antibody was labeled with streptavidin and the PSA standard products with concentrations of 0.003ng / ml, 0.1ng / ml, 4ng / ml and 10ng / ml were detected. The fluorescence values were 1100, 6800, 12100 and 42500 respectively. There was a good linear relationship between the fluorescence value and the concentration of the standard product. The minimum detection limit can reach 1×10 -12 ng / ml, indicating that the reagent has good accuracy.
[0134] 5. The trigger probe should be stored separately at 4°C and will not affect the test results within 12 months.
[0135] 6. The detection antibody, streptavidin and trigger probe are reacted to form a complex. The preparation method includes directly mixing 0.5% BSA in PBS at a certain ratio with a pH of 7.4-8. It can be stored at 4°C for 3 months without affecting the detection result, after which the detection effect is reduced.
[0136] Example 4
[0137] 1. Take PSA standard as the test object and use the following probes for detection:
[0138]
[0139] The preparation method of reagents A, B, C, and D is the same as that of Group 1 in Example 1.
[0140] The PSA standard (concentration 4 ng / ml) was tested with the above reagents, and the steps included:
[0141] 2.1. Mix reagent C and standard sample at 25℃, incubate for 30 minutes, and collect magnetic beads;
[0142] 2.2. The magnetic beads collected in step 2.1 were mixed with reagent D and reacted at 25°C for 40 minutes;
[0143] 2.3. Mix reagent A and reagent B and react at 37°C for 20 minutes;
[0144] 2.4. Place the solution in step 2.3 in step 2.2 and react at 37°C for 15-30 minutes;
[0145] 2.5. Remove the supernatant in step 2.4 by magnetic separation, wash the magnetic beads with PBST or PBS solution, and The fluorescence intensity was detected by ultra-high sensitivity multi-color flow cytometer.
[0146] The results showed that after repeated detection for 5 times, the average fluorescence value was 12910 and the RSD was 2.3%, indicating that the reagent has good repeatability. Its minimum detection limit can reach 1×10 -12ng / ml, indicating that the reagent has good accuracy.
[0147] Example 5
[0148] 1. Take PSA as the detection object and serum as the sample, and use the following probes for detection:
[0149]
[0150] The preparation method of reagents A, B, and C is the same as that of Group 1 in Example 1.
[0151] Reagent D: Prepare streptavidin-labeled detection antibody.
[0152] Reagent E: trigger probe.
[0153] 2. Use the above reagents to test the PSA standard product, the steps include:
[0154] 2.1. Mix reagent C and standard sample at 25℃, incubate for 30 minutes, and collect magnetic beads;
[0155] 2.2. The magnetic beads collected in step 2.1 were mixed with reagent D and reacted at 25°C for 40 minutes;
[0156] 2.3. Mix reagent A, reagent B and reagent E and react at 37°C for 20 minutes;
[0157] 2.4. Place the solution in step 2.3 in step 2.2 and react at 37°C for 15-30 minutes;
[0158] 2.5. Remove the supernatant in step 2.4 by magnetic separation, wash the magnetic beads with PBST or PBS solution, and The fluorescence intensity was detected by ultra-high sensitivity multi-color flow cytometer.
[0159] The results showed that after repeated detection for 3 times, the average fluorescence value was 12900 and the RSD was 1.6%, indicating that the reagent has good repeatability. Its minimum detection limit can reach 1×10 -12 ng / ml, indicating that the reagent has good accuracy.
[0160] Example 6
[0161] 1. Take PSA as the detection object and serum as the sample, and use the following probes for detection:
[0162]
[0163] The preparation method of reagents A, B, and C is the same as that of Group 1 in Example 1.
[0164] Reagent D: Prepare streptavidin-labeled detection antibody.
[0165] Reagent E: trigger probe.
[0166] 2. Use the above reagents to test the PSA standard product, the steps include:
[0167] 2.1. Mix reagent C and standard sample at 25℃, incubate for 30 minutes, and collect magnetic beads;
[0168] 2.2. The magnetic beads collected in step 2.1 were mixed with reagent D and reacted at 25°C for 40 minutes;
[0169] 2.3. Mix reagent A, reagent B and reagent E and react at 37°C for 20 minutes;
[0170] 2.4. Place the solution in step 2.3 in step 2.2 and react at 37°C for 15-30 minutes;
[0171] 2.5. Remove the supernatant in step 2.4 by magnetic separation, wash the magnetic beads with PBST or PBS solution, and The fluorescence intensity was detected by ultra-high sensitivity multi-color flow cytometer.
[0172] The results showed that after repeated detection for 3 times, the average fluorescence value was 12000 and the RSD was 1.5%, indicating that the reagent had good repeatability. Its minimum detection limit could reach 1×10 -12 ng / ml, indicating that the reagent has good accuracy.
[0173] Example 7
[0174] The following probes were used to detect PSA standards of different concentrations:
[0175]
[0176] 2. Use the above reagents to test the PSA standard product, the steps include:
[0177] 2.1. Mix reagent C and standard sample at 25℃, incubate for 30 minutes, and collect magnetic beads;
[0178] 2.2. The magnetic beads collected in step 2.1 were mixed with reagent D and reacted at 25°C for 40 minutes;
[0179] 2.3. Mix reagent A, reagent B and reagent E and react at 37°C for 20 minutes;
[0180] 2.4. Place the solution in step 2.3 in step 2.2 and react at 37°C for 15-30 minutes;
[0181] 2.5. Remove the supernatant in step 2.4 by magnetic separation, wash the magnetic beads with PBST or PBS solution, and The fluorescence intensity was detected by ultra-high sensitivity multi-color flow cytometer.
[0182] The results showed , The fluorescence values of PSA standards with concentrations of 0.003ng / ml, 0.1ng / ml, 4ng / ml, and 10ng / ml were 1100, 6800, 12100, and 42500, respectively. There was a good linear relationship between the fluorescence value and the concentration of the standard. This shows that the reagent has good repeatability. Its minimum detection limit can reach 1×10 -12 ng / ml, indicating that the reagent has good accuracy.
[0183] Example 8
[0184] Detection of serum samples: Under the experimental conditions of Example 7, the immune BHCR detection platform was used to detect the AFP concentration in the serum of liver cancer patients obtained from a hospital, and the AFP concentration value was close to that measured in the hospital. In addition, the value fluctuation of each sample was very small. The test results are as follows:
[0185] sample Example 7 Reagent Detection Data (ng / mL) 1 43.70±0.56 2 17.34±0.73 3 72.80±3.35
[0186] Specificity investigation: Under the conditions of Example 7, the immune BHCR detection platform was used to detect 1 ng / mL of AFP antigen and 100 ng / mL of non-target antigens (CEA, PSA, IgG). The results showed that the fluorescence intensity of AFP was significantly stronger than that of non-target antigens, indicating that the method has good specificity.
[0187] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention. Sequence Listing <110> Hunan Morning Nanorobot Co., Ltd. <120> A DNA dendrimer immunoassay reagent and method <130> MP21026374 <160> 7 <170> SIPOSequenceListing 1.0 <210> 1 <211> twenty three <212> DNA <213> Artificial Sequence <400> 1 tgacgaacta gttgatgaag ctg 23 <210> 2 <211> 5 <212> DNA <213> Artificial Sequence <400> 2 tgacg 5 <210> 3 <211> 12 <212> DNA <213> Artificial Sequence <400> 3 aactagttga tg 12 <210> 4 <211> 6 <212> DNA <213> Artificial Sequence <400> 4 aagctg 6 <210> 5 <211> twenty three <212> DNA <213> Artificial Sequence <400> 5 gtgtgcctat tatgtctcct cct 23 <210> 6 <211> 14 <212> DNA <213> Artificial Sequence <400> 6 gtgcctatta tgtc 14 <210> 7 <211> 7 <212> DNA <213> Artificial Sequence <400> 7 tcctcct 7
Claims
1. BHCR reaction reagent, characterized in that include: trigger probe, FA probe, QA probe, auxiliary A, FB probe, QB probe and auxiliary B; the 5' end of the trigger probe is labeled with biotin, the 5' ends of FA and QB are labeled with a fluorescent group, and the 3' ends of FB and QA are labeled with a quenching group; The sequence of the trigger probe consists of an isolation region and a trigger recognition region; the trigger recognition region consists of sequentially connected fragments a, b, and c. The sequence of the FA probe consists of 2 repeating units and a reverse complementary sequence of the trigger recognition region; each of the repeating units consists of sequentially connected fragments x, y and z; The sequence of the auxiliary A is composed of the reverse complementary sequence of 2 fragments y and 1 fragment c; The sequence of the QA probe consists of reverse complementary sequences of fragment b, fragment c and two fragments y; The sequence of the FB probe consists of a reverse complementary sequence of one repeating unit and the trigger recognition region sequence; The sequence of the auxiliary B is the reverse complementary sequence of 18 bp at the 5' end of the QB probe; The sequence of the QB probe consists of a reverse complementary sequence of the trigger recognition region lacking 7 bp at the 5' end, and a repeating unit sequence lacking 5 bp at the 3' end.
2. The BHCR reaction reagent according to claim 1, characterized in that The isolation region sequence of the trigger probe is ployA; the nucleic acid sequence of the trigger recognition region is TGACGAACTAGTTGATGAAGCTG, wherein fragment a is TGACG, fragment b is AACTAGTTGATG, and fragment c is AAGCTG.
3. The BHCR reaction reagent according to claim 1, characterized in that The sequence of the repeating unit is GTGTGCCTATTATGTCTCCTCCT, wherein the fragment x is GT, the fragment y is GTGCCTATTATGTC, and the fragment z is TCCTCCT.
4. The BHCR reaction reagent according to claim 1, characterized in that The fluorescent group is 6-FAM, and the quenching group is BHQ1.
5. Use of the BHCR reaction reagent according to any one of claims 1 to 4 in the preparation of instant test reagents.
6. A reagent for instant testing, comprising: igger probe, reagent A, reagent B, reagent C and reagent D; The reagent A comprises the FA probe, QA probe and auxiliary A according to any one of claims 1 to 4; The reagent B comprises the FB probe, QB probe and auxiliary B according to any one of claims 1 to 4; The reagent C comprises magnetic beads coated with capture antibodies; The trigger probe and the detection antibody labeled with avidin form a complex, which is recorded as reagent D; Alternatively, the detection antibody labeled with avidin is recorded as reagent D, and the trigger probe existing independently is recorded as reagent E.
7. The reagent according to claim 6, characterized in that: The preparation of the reagent A comprises: cooling the FA probe and the QA probe from 90 to 95° C. at a rate of 1 min / ° C. to 55° C., then cooling them naturally to room temperature, and then adding auxiliary A to obtain the reagent A; The preparation of the reagent B comprises: cooling the FB probe and the QB probe from 90-95° C. to 55° C. at a rate of 1 min / ° C., and then cooling them naturally to room temperature, and then adding auxiliary B to obtain the reagent B.
8. The reagent according to claim 6, characterized in that: The preparation of the complex formed by the trigger probe and the detection antibody labeled with avidin includes: after labeling the detection antibody with avidin, mixing it with the trigger probe in PBS containing 0.5% BSA, and incubating to obtain the complex.
9. A non-diagnostic point-of-care detection method, characterized in that: include: The analyte is detected using the reagent described in claim 7 or 8.
